This study investigated the safety and effectiveness of peficitinib (Smyraf) in rheumatoid arthritis (RA). 

They found that peficitinib improved RA symptoms and slowed joint damage. 

This study examined if dapagliflozin (Farxiga) and saxagliptin (Onglyza) improved symptoms of kidney disease in patients with type 2 diabetes and kidney disease. The authors concluded that dapagliflozin with or without saxagliptin reduced kidney disease symptoms and lowered blood glucose levels in these patients.

This study is evaluating the impact of an education program plus nutritional supplements on the frequency of eye disease in patients with diabetes mellitus. The main outcome to be measured will be the changes in electroretinogram results, a lab test that measures vision quality. This study is recruiting in North Carolina.

This study evaluated the safety and effectiveness of ipragliflozin (Suglat) in patients with type 2 diabetes (T2D). This study concluded that ipragliflozin helped reduce insulin dose by 30%, with minimal side effects.

This study investigated the effects of glucagon-like peptide 1 receptor agonists (GLP-1Ra) in patients with diabetes. 

They found that GLP-1Ra drugs improved cardiovascular (CV), kidney and mortality outcomes. 

This study investigated the risk factors associated with diabetic retinopathy (DR). The authors concluded that factors such as age, total cholesterol, and the presence of other health complications could increase the risk of DR in patients with Type 2 diabetes (T2D).

This study investigated whether 3 meals a day improved blood glucose control and weight loss compared to 6 meals a day for patients with Type 2 diabetes (T2D). This study found that fewer meals a day improved blood glucose control and weight loss and reduced hunger and cravings.

This study compared the safety and effectiveness of oral semaglutide with liraglutide administered via subcutaneous (under the skin) injection in patients with type 2 diabetes (T2D). The authors concluded that both treatments were similarly safe and effective in these patients.

This study evaluated the impact of long-term pioglitazone (Actos) treatment on outcomes for patients with type 2 diabetes (T2D) taking insulin. The authors concluded that this treatment lowered mortality risk for these patients.

This study assessed the effect of dulaglutide (Trulicity) on heart disease risk in patients with type 2 diabetes (T2D). The authors concluded that dulaglutide is an optimal treatment for patients with T2D at risk of heart disease.